High Helicobacter pylori Resistance to Metronidazole but Zero or Low Resistance to Clarithromycin, Levofloxacin, and Other Antibiotics in Malaysia

Helicobacter

Volumn 16, Issue 3, 2011, Pages 241-245

  Goh, Khean Lee ^a   Navaratnam, Parasakthi ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Clarithromycin; H. pylori resistance; Levofloxacin; Malaysia; Metronidazole; Rifabutin

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; NITROFURANTOIN; RIFABUTIN; RIFAMPICIN; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; EPSILOMETER TEST; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STOMACH BIOPSY; TREND STUDY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; PROSPECTIVE STUDIES;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 79956085805     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2011.00841.x     Document Type: Article

References (40)

1. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15year period in Italy. J Antimicrob Chemother 2007;59:783-5.
2. Vécsei A, Kipet A, Innerhofer A, et al. Time trends of Helicobacter pylori resistance to antibiotics in children living in Vienna, Austria. Helicobacter 2010;15:214-20.
3. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007;45:4006-10.
4. Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009;14:86-90.
5. Kato S. Helicobacter pylori eradication therapy in children. Nippon Rinsho 2009;67:2311-6.
6. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10years in Beijing, China. Helicobacter 2010;15:460-6.
7. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010;16:5118-21.
8. Gu Q, Xia HH, Wang JD, et al. Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy. Digestion 2006;73:101-6.
9. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009;24:1230-5.
10. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
11. Parasakthi N, Goh KL. Metronidazole resistance among Helicobacter pylori strains in Malaysia. Am J Gastroenterol 1992;87:808. (Letter).
12. Parasakthi N, Goh KL. Primary and acquired Clarithromycin resistance amongst Helicobacter pylori strains in Malaysia. Am J Gastroenterol 1995;90:519.
13. Goh KL, Parasakthi N, Chuah SY, Toetsch M. Combination amoxicillin and metronidazole with famotidine in the eradication of Helicobacter pylori -a randomised double blind comparison of a three times daily and twice daily regimen. Eur J Gastroenterol Hepatol 1997;9:1091-5.
14. Goh KL, Parasakthi N, Chuah SY, Cheah PI, Lo YL, Chin SC. One-week low dose triple therapy with proton-pump inhibitors-optimal therapy for H. pylori eradication? Alim Pharm Ther 1997;11:1115-8.
15. Goh KL, Parasakthi N, Cheah PL, Ranjeev P, Mohammad R, Tan Y, Chin S. The efficacy of a one week pantoprazole triple therapy in eradicating Helicobacter pylori in Malaysian patients. J Gastroenterol Hepatol 2000;15:910-4.
16. Ho SL, Tan EL, Sam CK, Goh KL. Clarithromycin resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Malaysia. J Dig Dis 2010;11:101-5.
17. Fujimura S, Kato S, Kawamura T, Watanabe A. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother 2002;49:541-3.
18. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-9.
19. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
20. Ducóns JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollón F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999;13:775-80.
21. Lee JH, Shin JH, Roe IH, Sohn SG, Lee JH, Kang GH, Lee HK, Jeong BC, Lee SH. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005;49:1600-3.
22. Megraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 1998;43:S61-5.
23. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55. Review.
24. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57.
25. Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006;55:1711-6.
26. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84. Review.
27. Loivukene K, Maaroos HI, Kolk H, Kull I, Labotkin K, Mikelsaar M. Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clin Microbiol Infect 2002;8:598-603.
28. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002;7:306-9.
29. Ahmad N, Zakaria WR, Abdullah SA, Mohamed R. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World J Gastroenterol 2009;15:3161-5.
30. Qua CS, Manikam J, Goh KL. Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10years on? J Dig Dis 2010;11:244-8.
31. Hung IF, Chan P, Leung S, et al. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter 2009;14:505-11.
32. Goh KL, Mahendra Raj S, Parasakthi N, Kew ST, Kandasami P, Mazlam Z. Management of Helicobacter pylori infection - a Working Party Report of the Malaysian Society of Gastroenterology and Hepatology. Med J Malaysia 1998;53:302-10.
33. Tseng YS, Wu DC, Chang CY, Kuo CH, Yang YC, Jan CM, Su YC, Kuo FC, Chang LL. Amoxicillin resistance with beta-lactamase production in Helicobacter pylori. Eur J Clin Invest 2009;39:807-12.
34. Hung KH, Sheu BS, Chang WL, et al. Prevalence of primary fluoroquinolone resistance among clinic isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009;14:61-5.
35. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007;29:389-96.
36. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005;56:965-7.
37. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006;28:6-13.
38. Goh KL, Manikam J, Qua CS. Highly successful sequential therapy as rescue treatment for Helicobacter treatment failures. J Gastroenterol Hepatol 2010;25:A170.
39. Jetan CA, Jamaiah I, Rohela M, Nissapatorn V. Tuberculosis: an eight year (2000-2007) retrospective study at the University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. Southeast Asian J Trop Med Public Health 2010;41:378-85.
40. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.